Details of Disease

General Information of Disease (ID: DIS4W15K)

• Disease Name: Cachexia
• Synonyms: congenital absence of hand
• Disease Class: MG20: Cachexia
• Disease Hierarchy:
  DISHPNVX: Dysplasia
  DIS5Z8U6: Skeletal dysplasia
  DIS4W15K: Cachexia
• ICD Code:
  ICD-11: ICD-11: MG20
  ICD-10: ICD-10: R64
  ICD-9: ICD-9: 799.4
  Expand ICD-11: 'MG20
  Expand ICD-10: 'R64
  Expand ICD-9: 799.4
• Disease Identifiers:
  MONDO ID: MONDO_0017445
  MESH ID: D002100
  UMLS CUI: C0265594
  MedGen ID: 488815
  HPO ID: HP:0004050
  Orphanet ID: 294983
  SNOMED CT ID: 1003510009

Drug-Interaction Atlas (DIA) of This Disease

This Disease is Treated as An Indication in 8 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
RM-131	DMD709J	Phase 3	NA	[1]
APD-209	DMNQ7DV	Phase 2	NA	[2]
Betamarc	DMMMZH6	Phase 2	NA	[3]
CJC-1295	DMLACBI	Phase 2	Small molecular drug	[4]
OHR/AVR118	DMS6ABV	Phase 2	NA	[5]
PH-284	DMVOESJ	Phase 2	NA	[6]
Kanglaite	DMWXYX9	Phase 1	NA	[7]
PF-05230901	DMMYPM9	Phase 1	NA	[8]

This Disease is Treated as An Indication in 3 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
PF-06260414	DMSE3WP	Discontinued in Phase 1	NA	[9]
MNX-160	DM4FX31	Terminated	NA	[11]
Steroid hormone conjugates	DMOJM08	Terminated	NA	[12]

This Disease is Treated as An Indication in 1 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
GLPG-0492	DMSW07R	Preclinical	NA	[10]

This Disease is Treated as An Indication in 6 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ACE-435	DMOJGF3	Investigative	NA	[13]
AMX-213	DMGPRBF	Investigative	NA	[14]
BL-5040	DMGULNZ	Investigative	NA	[15]
BL-6020	DMQLJMC	Investigative	NA	[16]
Dehydroxymethylepoxyquinomicin	DMPCE5P	Investigative	Small molecular drug	[14]
EX-1314	DMWF8U5	Investigative	Small molecular drug	[17]

Molecular Interaction Atlas (MIA) of This Disease

References

• [1] ClinicalTrials.gov (NCT02357420) A Study to Evaluate the Safety and Efficacy of RM-131 Administered to Patients With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis. U.S. National Institutes of Health.
• [2] ClinicalTrials.gov (NCT01977443) Therapeutic Efficacy of APD-209 Eye Drops in Treatment of Epidemic Keratoconjunctivitis (EKC). U.S. National Institutes of Health.
• [3] ClinicalTrials.gov (NCT00535015) Safety and Efficacy Study of Betamarc to Treat Loss of Weight and Appetite in Non-Small Cell Lung Cancer. U.S. National Institutes of Health.
• [4] ClinicalTrials.gov (NCT00267527) A Study to Evaluate CJC 1295 in HIV Patients With Visceral Obesity. U.S. National Institutes of Health.
• [5] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800004777)
• [6] Pharma-Nutrition: An Overview, Gert Folkerts. Page(261).
• [7] ClinicalTrials.gov (NCT00031031) Kanglaite Injection Phase I Study. U.S. National Institutes of Health.
• [8] ClinicalTrials.gov (NCT01262690) A Study In Healthy Subjects Of Single Doses of PF-05230901 Injected Under The Skin. U.S. National Institutes of Health.
• [9] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040072)
• [10] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018432)
• [11] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007392)
• [12] Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015954)
• [13] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1788).
• [14] The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
• [15] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1712).
• [16] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 285).
• [17] URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 246).